Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: A case report

Annals of Hematology

Volumn 89, Issue 4, 2010, Pages 421-422

  Eo, Wan Kyu ^a   Kim, Se Hyun ^c   Cheon, Seong Ha ^a   Lee, Sang Hun ^a   Jeong, Jong Soo ^a   Kim, Yang Soo ^b   Chang, Hee Kyung ^b   Suh, Kee Suck ^b   Kim, Heung Yeol ^b  

^a Kyung Hee University College of Medicine   (South Korea)

^b Kosin University   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN; IV GLOBULIN S; MELPHALAN; PREDNISONE; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

AGED; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SKIN BIOPSY; SKIN MANIFESTATION; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT RESPONSE; BIOPSY; IMMUNOLOGY; PATHOLOGY;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; DEXAMETHASONE; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 77649281023     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0810-y     Document Type: Letter

References (9)

1. Pereira FA, Mudgil AV, Rosmarin DM (2007) Toxic epidermal necrolysis. J Am Acad Dermatol 56:181-200. doi:10.1016/j. jaad.2006.04.048
2. Revuz J, Roujeau JC, Guillaume JC, Penso D, Touraine R (1987) Treatment of toxic epidermal necrolysis. Créteil's experience. Arch Dermatol 123:1156-1158. doi:10.1001/archderm.123.9.1156 (Pubitemid 17119308)
3. Horowitz SB, Stirling AL (1999) Thalidomide-induced toxic epidermal necrolysis. Pharmacotherapy 19:1177-1180. doi:10.1592/phco.19.15.1177.30571 (Pubitemid 29455940)
4. Rajkumar SV, Gertz MA, Witzig TE (2000) Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 343:972-973. doi:10.1056/NEJM200009283431315
5. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115:149-153. doi:10.1046/j.1523-1747.2000.00061.x (Pubitemid 30637181)
6. Hall VC, El-Azhary RA, Bouwhuis S, Rajkumar SV (2003) Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol 48:548-552. doi:10.1067/mjd. 2003.87
7. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319-4323. doi:10.1200/JCO.2002.02.116 (Pubitemid 35266292)
8. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE, TEN-IVIG Study Group (2003) Toxic epidermal necrolysisintravenous immunoglobulin. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139:26-32. doi:10.1001/archderm.139.1.26 (Pubitemid 36091570)
9. Trent JT, Kirsner RS, Romanelli P, Kerdel FA (2003) Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 139:39-43. doi:10.1001/archderm.139.1.39 (Pubitemid 36091572)